Neuraminidase H275Y and hemagglutinin D222G mutations in a fatal case of 2009 pandemic influenza A (H1N1) virus infection

Influenza and other Respiratory Viruses

Volumn 6, Issue 6, 2012, Pages

  Devries, Aaron ^a   Wotton, Jason ^a   Lees, Christine ^a   Boxrud, David ^a   Uyeki, Timothy ^b   Lynfield, Ruth ^a  

^a MINNESOTA DEPARTMENT OF HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

2009 H1N1; Fatal; Oseltamivir; Pandemic influenza; Pyrosequencing; Resistance; Severity

Indexed keywords

COTRIMOXAZOLE; HEMAGGLUTININ D222G; LEVOFLOXACIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEURAMINIDASE H275Y; OSELTAMIVIR; PREDNISONE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

2009 H1N1 INFLUENZA; ADULT; ARTICLE; ASPERGILLOSIS; CASE REPORT; COUGHING; DYSPNEA; GENE MUTATION; GLOMERULONEPHRITIS; HEMAGGLUTINATION; HUMAN; IMMUNE DEFICIENCY; LUNG LAVAGE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; RISK; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; VIRUS HEMAGGLUTINATION; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; DRUG RESISTANCE, VIRAL; FATAL OUTCOME; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS;

EID: 84867705812     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2011.00329.x     Document Type: Article

References (18)

1. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-1719.
2. Miller RR, MacLean AR, Gunson RN, Carman WF. Occurrence of haemagglutinin mutation D222G in pandemic influenza A(H1N1) infected patients in the West of Scotland, United Kingdom, 2009-10. Euro Surveill 2010; 15(16):pii=19546.
3. Chutinimitkul S, Herfst S, Steel J et al. Virulence-associated substitution D222G in hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J Virol 2010; 84:11802-11813.
4. World Health Organization. CDC protocol of realtime RTPCR for influenza A(H1N1) revision 2. 2009; Available at http://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf (cited 2 August 2010).
5. World Health Organization. CDC pyrosequencing assay to detect H275Y mutation in the neuraminidase of novel A (H1N1) viruses. 2009; Available at http://www.who.int/csr/resources/publications/swineflu/NA_DetailedPyrosequencing_20090513.pdf (Accessed 2 August 2010).
6. Deyde VM, Sheu TG, Trujillo AA et al. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 2010; 54:1102-1110.
7. Levine M, Sheu TG, Gubareva LV, Mishin VP. Detection of hemagglutinin variants of the pandemic influenza A(H1N1) 2009 virus by pyrosequencing. J Clin Microbiol 2011; 49:1307-1312.
8. World Health Organization. Preliminary review of D222G amino acid substitution in the haemagglutinin of pandemic influenza A (H1N1) 2009 viruses. Wkly Epidemiol Rec 2010; 85:21-28.
9. Lat A, Bhadelia N, Miko B, Furuya EY, Thompson GR III. Invasive Aspergillosis after Pandemic (H1N1) 2009. Emerg Infect Dis 2010; 16:971-973.
10. Centers for Disease Control and Prevention. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:969-972.
11. Tramontana AR, George B, Hurt AC et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010; 16:1068-1075.
12. Calatayud L, Lackenby A, Reynolds A et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. Emerg Infect Dis 2011; 17:1807-1815.
13. Fiore AE, Fry A, Shay D et al. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
14. World Health Organization. WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. Revised February 2010. Available at http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.
15. Stevens J, Blixt O, Glaser L et al. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol 2006; 355:1143-1155.
16. Chan PK, Lee N, Joynt GM et al. Clinical and virological course of infection with haemagglutinin D222G mutant strain of 2009 pandemic influenza A (H1N1) virus. J Clin Virol 2011; 50:320-324.
17. Baldanti F, Campanini G, Piralla A et al. Severe outcome of influenza A/H1N1/09v infection associated with 222G/N polymorphisms in the haemagglutinin: a multicentre study. Clin Microbiol Infect 2011; 17:1166-1169.
18. Govorkova EA, Matrosovich MN, Tuzikov AB et al. Selection of receptor-binding variants of human influenza A and B viruses in baby hamster kidney cells. Virology 1999; 262:31-38.